Advertisement

Topics

Everolimus, CB-839 Combination Active in Advanced RCC

20:00 EST 1 Dec 2016 | Cancer Networks

The combination of CB-839, a selective inhibitor of glutaminase, and everolimus seems to have disease activity in patients with advanced renal cell carcinoma.

Original Article: Everolimus, CB-839 Combination Active in Advanced RCC

NEXT ARTICLE

More From BioPortfolio on "Everolimus, CB-839 Combination Active in Advanced RCC"

Quick Search
Advertisement
 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...